Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Tumour Necrosis Factor Inhibitor Drugs Market: By Type: Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, Biosimilars; By End Use: Rheumatoid Arthritis, Psoriasis, Others; Regional Analysis; Historical Market and Forecast (2018-2028); Market Dynamics; Competitive Landscape; Industry Events and Developments

Global Tumour Necrosis Factor Inhibitor Drugs Market Outlook

The global tumour necrosis factor inhibitor drugs market attained a value of around USD 40.3 billion in 2020. The market is further expected to grow in the forecast period of 2023-2028 at a CAGR of around 0.7% to reach USD 42 billion by 2026.

 

Global Tumour Necrosis Factor Inhibitor Drugs Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The market is significantly being aided by the growing awareness among consumers about Tumour Necrosis Factor (TNF). North America is the leading region, whereas the Asia Pacific is expected to witness the fastest growth in the forecast period.

 

Market Segmentation

Tumour necrosis factor inhibitor are organic medicines derived from humans or animals’ tissues and most widely used by blocking the inflammatory substance, that is, the tumour necrosis factor in the body to stop inflammation and progression of the disease. It is recommended mainly for treating multiple inflammatory disorders, including rheumatoid arthritis and psoriasis.

 

Global Tumour Necrosis Factor Inhibitor Drugs Market By Type

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Based on type, the market can be divided into:

  • Humira
  • Enbrel
  • Remicade
  • Simponi/Simponi Aria
  • Cimzia
  • Biosimilars

The market can be broadly categorised based on its end-uses into:

  • Rheumatoid arthritis
  • Psoriasis
  • Psoriatic Arthritis
  • Crohn's Disease
  • Ulcerative Colitis
  • Ankylosing Spondylitis
  • Juvenile Idiopathic Arthritis
  • Hidradenitis Suppurativa
  • Others

The EMR report looks into the regional markets of tumour necrosis factor inhibitor drugs like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

 

Global Tumour Necrosis Factor Inhibitor Drugs Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

The market for tumour necrosis factor inhibitor drugs is driven by the increased prevalence of several inflammatory disorders, like rheumatoid arthritis and inflammatory bowel disease in North America. Europe has also been a significant part of the global market due to a robust geriatric population, which is more vulnerable to inflammatory conditions. The increased incidences of different inflammatory diseases and the entrance in the market of the biosimilar are likely to increase both the availability and the usage of the tumour necrosis factor inhibitor drugs, which, in effect, will boost the market during the forecast period. In addition, low manufacturing costs in China and India have led to an increase in the number of plants attracting pharmaceutical and biotechnological giants from all over the world.

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global tumour necrosis factor inhibitor drugs market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • AbbVie, Inc. (NYSE: ABBV)
  • Amgen, Inc. 
  • Johnson & Johnson Services, Inc.
  • UCB S.A. 
  • Pfizer, Inc. 
  • Novartis International AG 
  • Merck & Co., Inc. 
  • Others

The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

REPORT FEATURES DETAILS
Base Year 2022
Historical Period 2018-2022
Forecast Period 2023-2028
Scope of the Report Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Type, End Use, Region
Breakup by Type Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, Biosimilars
Breakup by End Use Rheumatoid arthritis, Psoriasis, Psoriatic arthritis, Crohn's Disease, Ulcerative colitis, Ankylosing Spondylitis, Juvenile idiopathic arthritis, Hidradenitis suppurativa, Others
Breakup by Region North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Market Dynamics SWOT, Porter's Five Forces, Key Indicators for Price and Demand
Competitive Landscape Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications
Companies Covered AbbVie, Inc. (NYSE: ABBV), Amgen, Inc. (NASDAQ: AMGN), Johnson & Johnson Services, Inc., UCB S.A. (EBR: UCB), Pfizer, Inc. (NYSE: PFE), Novartis International AG (SWX: NOVN), Merck & Co., Inc. (NYSE: MRK), Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Opportunities and Challenges in the Market
8    Global Tumour Necrosis Factor Inhibitor Drugs Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Tumour Necrosis Factor Inhibitor Drugs Historical Market (2018-2022) 
    8.3    Global Tumour Necrosis Factor Inhibitor Drugs Market Forecast (2023-2028)
    8.4    Global Tumour Necrosis Factor Inhibitor Drugs Market by Type
        8.4.1    Humira
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2018-2022)
            8.4.1.3    Forecast Trend (2023-2028)
        8.4.2    Enbrel
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2018-2022)
            8.4.2.3    Forecast Trend (2023-2028)
        8.4.3    Remicade
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2018-2022)
            8.4.3.3    Forecast Trend (2023-2028)
        8.4.4    Simponi/Simponi Aria
            8.4.4.1    Market Share
            8.4.4.2    Historical Trend (2018-2022)
            8.4.4.3    Forecast Trend (2023-2028)
        8.4.5    Cimzia
            8.4.5.1    Market Share
            8.4.5.2    Historical Trend (2018-2022)
            8.4.5.3    Forecast Trend (2023-2028)
        8.4.6    Biosimilars
            8.4.6.1    Market Share
            8.4.6.2    Historical Trend (2018-2022)
            8.4.6.3    Forecast Trend (2023-2028)
    8.5    Global Tumour Necrosis Factor Inhibitor Drugs Market by End Use
        8.5.1    Rheumatoid Arthritis
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2018-2022)
            8.5.1.3    Forecast Trend (2023-2028)
        8.5.2    Psoriasis
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2018-2022)
            8.5.2.3    Forecast Trend (2023-2028)
        8.5.3    Psoriatic Arthritis
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2018-2022)
            8.5.3.3    Forecast Trend (2023-2028)
        8.5.4    Crohn’s Disease
            8.5.4.1    Market Share
            8.5.4.2    Historical Trend (2018-2022)
            8.5.4.3    Forecast Trend (2023-2028)
        8.5.5    Ulcerative Colitis
            8.5.5.1    Market Share
            8.5.5.2    Historical Trend (2018-2022)
            8.5.5.3    Forecast Trend (2023-2028)
        8.5.6    Ankylosing Spondylitis
            8.5.6.1    Market Share
            8.5.6.2    Historical Trend (2018-2022)
            8.5.6.3    Forecast Trend (2023-2028)
        8.5.7    Juvenile Idiopathic Arthritis
            8.5.7.1    Market Share
            8.5.7.2    Historical Trend (2018-2022)
            8.5.7.3    Forecast Trend (2023-2028)
        8.5.8    Hidradenitis Suppurativa
            8.5.8.1    Market Share
            8.5.8.2    Historical Trend (2018-2022)
            8.5.8.3    Forecast Trend (2023-2028)
        8.5.9    Others
    8.6    Global Tumour Necrosis Factor Inhibitor Drugs Market by Region
        8.6.1    North America
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2018-2022) 
            8.6.1.3    Forecast Trend (2023-2028)
        8.6.2    Europe
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2018-2022) 
            8.6.2.3    Forecast Trend (2023-2028)
        8.6.3    Asia Pacific
            8.6.3.1    Market Share
            8.6.3.2    Historical Trend (2018-2022) 
            8.6.3.3    Forecast Trend (2023-2028)
        8.6.4    Latin America
            8.6.4.1    Market Share
            8.6.4.2    Historical Trend (2018-2022) 
            8.6.4.3    Forecast Trend (2023-2028)
        8.6.5    Middle East and Africa
            8.6.5.1    Market Share
            8.6.5.2    Historical Trend (2018-2022) 
            8.6.5.3    Forecast Trend (2023-2028) 
9    North America Tumour Necrosis Factor Inhibitor Drugs Market Analysis
    9.1    United States of America 
        9.1.1    Market Share
        9.1.2    Historical Trend (2018-2022) 
        9.1.3    Forecast Trend (2023-2028)
    9.2    Canada
        9.2.1    Market Share
        9.2.2    Historical Trend (2018-2022) 
        9.2.3    Forecast Trend (2023-2028)
10    Europe Tumour Necrosis Factor Inhibitor Drugs Market Analysis
    10.1    United Kingdom
        10.1.1    Market Share
        10.1.2    Historical Trend (2018-2022) 
        10.1.3    Forecast Trend (2023-2028)
    10.2    Germany
        10.2.1    Market Share
        10.2.2    Historical Trend (2018-2022) 
        10.2.3    Forecast Trend (2023-2028)
    10.3    France
        10.3.1    Market Share
        10.3.2    Historical Trend (2018-2022) 
        10.3.3    Forecast Trend (2023-2028)
    10.4    Italy
        10.4.1    Market Share
        10.4.2    Historical Trend (2018-2022) 
        10.4.3    Forecast Trend (2023-2028)
    10.5    Others
11    Asia Pacific Tumour Necrosis Factor Inhibitor Drugs Market Analysis
    11.1    China
        11.1.1    Market Share
        11.1.2    Historical Trend (2018-2022) 
        11.1.3    Forecast Trend (2023-2028)
    11.2    Japan
        11.2.1    Market Share
        11.2.2    Historical Trend (2018-2022) 
        11.2.3    Forecast Trend (2023-2028)
    11.3    India
        11.3.1    Market Share
        11.3.2    Historical Trend (2018-2022) 
        11.3.3    Forecast Trend (2023-2028)
    11.4    ASEAN
        11.4.1    Market Share
        11.4.2    Historical Trend (2018-2022) 
        11.4.3    Forecast Trend (2023-2028)
    11.5    Australia
        11.5.1    Market Share
        11.5.2    Historical Trend (2018-2022) 
        11.5.3    Forecast Trend (2023-2028)
    11.6    Others
12    Latin America Tumour Necrosis  Factor Inhibitor Drugs Market Analysis
    12.1    Brazil
        12.1.1    Market Share
        12.1.2    Historical Trend (2018-2022) 
        12.1.3    Forecast Trend (2023-2028)
    12.2    Argentina
        12.2.1    Market Share
        12.2.2    Historical Trend (2018-2022) 
        12.2.3    Forecast Trend (2023-2028)
    12.3    Mexico
        12.3.1    Market Share
        12.3.2    Historical Trend (2018-2022) 
        12.3.3    Forecast Trend (2023-2028)
    12.4    Others
13    Middle East and Africa Tumour Necrosis Factor Inhibitor Drugs Market Analysis
    13.1    Saudi Arabia
        13.1.1    Market Share
        13.1.2    Historical Trend (2018-2022) 
        13.1.3    Forecast Trend (2023-2028)
    13.2    United Arab Emirates
        13.2.1    Market Share
        13.2.2    Historical Trend (2018-2022) 
        13.2.3    Forecast Trend (2023-2028)
    13.3    Nigeria
        13.3.1    Market Share
        13.3.2    Historical Trend (2018-2022) 
        13.3.3    Forecast Trend (2023-2028)
    13.4    South Africa
        13.4.1    Market Share
        13.4.2    Historical Trend (2018-2022) 
        13.4.3    Forecast Trend (2023-2028)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
    14.3    Key Indicators for Demand
    14.4    Key Indicators for Price
15    Value Chain Analysis
16    Competitive Landscape

    16.1    Market Structure
    16.2    Company Profiles
        16.2.1    AbbVie, Inc. (NYSE: ABBV)
            16.2.1.1    Company Overview
            16.2.1.2    Product Portfolio
            16.2.1.3    Demographic Reach and Achievements
            16.2.1.4    Certifications
        16.2.2    Amgen, Inc. (NASDAQ: AMGN)
            16.2.2.1    Company Overview
            16.2.2.2    Product Portfolio
            16.2.2.3    Demographic Reach and Achievements
            16.2.2.4    Certifications
        16.2.3    Johnson & Johnson Services, Inc.
            16.2.3.1    Company Overview
            16.2.3.2    Product Portfolio
            16.2.3.3    Demographic Reach and Achievements
            16.2.3.4    Certifications
        16.2.4    UCB S.A. (EBR: UCB)
            16.2.4.1    Company Overview
            16.2.4.2    Product Portfolio
            16.2.4.3    Demographic Reach and Achievements
            16.2.4.4    Certifications
        16.2.5    Pfizer, Inc. (NYSE: PFE)
            16.2.5.1    Company Overview
            16.2.5.2    Product Portfolio
            16.2.5.3    Demographic Reach and Achievements
            16.2.5.4    Certifications
        16.2.6    Novartis International AG (SWX: NOVN)
            16.2.6.1    Company Overview
            16.2.6.2    Product Portfolio
            16.2.6.3    Demographic Reach and Achievements
            16.2.6.4    Certifications
        16.2.7    Merck & Co., Inc. (NYSE: MRK)
            16.2.7.1    Company Overview
            16.2.7.2    Product Portfolio
            16.2.7.3    Demographic Reach and Achievements
            16.2.7.4    Certifications
        16.2.8    Others
17    Key Trends and Developments in the Market


List of Key Figures and Tables

1.    Global Tumour Necrosis Factor Inhibitor Drugs Market: Key Industry Highlights, 2018 and 2028
2.    Global Tumour Necrosis Factor Inhibitor Drugs Historical Market: Breakup by Type (USD Billion), 2018-2022
3.    Global Tumour Necrosis Factor Inhibitor Drugs Market Forecast: Breakup by Type (USD Billion), 2023-2028
4.    Global Tumour Necrosis Factor Inhibitor Drugs Historical Market: Breakup by End Use (USD Billion), 2018-2022
5.    Global Tumour Necrosis Factor Inhibitor Drugs Market Forecast: Breakup by End Use (USD Billion), 2023-2028
6.    Global Tumour Necrosis Factor Inhibitor Drugs Historical Market: Breakup by Region (USD Billion), 2018-2022
7.    Global Tumour Necrosis Factor Inhibitor Drugs Market Forecast: Breakup by Region (USD Billion), 2023-2028
8.    North America Tumour Necrosis Factor Inhibitor Drugs Historical Market: Breakup by Country (USD Billion), 2018-2022
9.    North America Tumour Necrosis Factor Inhibitor Drugs Market Forecast: Breakup by Country (USD Billion), 2023-2028
10.    Europe Tumour Necrosis Factor Inhibitor Drugs Historical Market: Breakup by Country (USD Billion), 2018-2022
11.    Europe Tumour Necrosis Factor Inhibitor Drugs Market Forecast: Breakup by Country (USD Billion), 2023-2028
12.    Asia Pacific Tumour Necrosis Factor Inhibitor Drugs Historical Market: Breakup by Country (USD Billion), 2018-2022
13.    Asia Pacific Tumour Necrosis Factor Inhibitor Drugs Market Forecast: Breakup by Country (USD Billion), 2023-2028
14.    Latin America Tumour Necrosis Factor Inhibitor Drugs Historical Market: Breakup by Country (USD Billion), 2018-2022
15.    Latin America Tumour Necrosis Factor Inhibitor Drugs Market Forecast: Breakup by Country (USD Billion), 2023-2028
16.    Middle East and Africa Tumour Necrosis Factor Inhibitor Drugs Historical Market: Breakup by Country (USD Billion), 2018-2022
17.    Middle East and Africa Tumour Necrosis Factor Inhibitor Drugs Market Forecast: Breakup by Country (USD Billion), 2023-2028
18.    Global Tumour Necrosis Factor Inhibitor Drugs Market Structure

Key Questions Answered in the Report

In 2020, the global tumour necrosis factor inhibitor drugs market attained a value of nearly USD 40.3 billion.

The market is projected to grow at a CAGR of 0.7% between 2021 and 2026.

The market is estimated to witness a healthy growth in the forecast period of 2023-2028 to reach about USD 42 billion by 2026.

The major drivers of the industry, such as the growing awareness among consumers about TNF, increased prevalence of several inflammatory disorders, and low manufacturing costs, are expected to aid the market growth.

The key market trend guiding the industry growth includes the growing development and manufacture of new products.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share in the market.

The leading types of tumour necrosis factor inhibitor drugs in the industry are Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, and biosimilars.

The major end uses of these drugs are rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, juvenile idiopathic arthritis, and hidradenitis suppurativa, among others.

The major players in the industry are AbbVie, Inc., Amgen, Inc., Johnson & Johnson Services, Inc., UCB S.A., Pfizer, Inc., Novartis International AG, and Merck & Co., Inc., among others.

Analyst Review

The global tumour necrosis factor inhibitor drugs market attained a value of USD 40.3 billion in 2020, driven by the increased incidences of different inflammatory diseases. Aided by the development of new products, the market is expected to witness a further growth in the forecast period of 2023-2028, growing at a CAGR of 0.7%. The market is projected to reach USD 42 billion by 2026.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its types, the tumour necrosis factor inhibitor drugs industry can be segmented into Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, and biosimilars. On the basis of end uses, the industry is divided into rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, juvenile idiopathic arthritis, hidradenitis suppurativa, and others.  The major regional markets for tumour necrosis factor inhibitor drugs are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa, with North America accounting for the largest share of the market. The key players in the above market include AbbVie, Inc., Amgen, Inc., Johnson & Johnson Services, Inc., UCB S.A., Pfizer, Inc., Novartis International AG, Merck & Co., Inc., and others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER